Navamya Acharya

Investing.com -- Earnings season for Stoxx 600 companies is progressing with stronger-than-expected results in the fourth quarter, though near-term expectations remain under...

Investing.com -- Gubra (CSE:GUBRA) shares surged over 23% on Monday after the Danish biotech company announced a licensing deal with U.S. pharmaceutical giant AbbVie (NYSE:ABBV) to...

Investing.com -- U.S. President Donald Trump's plan to impose 25% tariffs on imports from the European Union could further strain economic growth in Central Europe and exacerbate...

Investing.com -- Bunzl (LON:BNZL) shares fell more than 6% on Monday despite the company reporting full-year 2024 results that aligned with market expectations. Investors...

Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE:GSK)'s biologics license application for depemokimab, a monoclonal antibody targeting...

Investing.com -- BCA Research has upgraded its recommendation on Euro Area equities to “overweight” from “neutral” in a global equity portfolio, citing structural improvements in...

Investing.com -- The UK pension risk transfer market is set for another active year in 2025, driven by continued demand from pension schemes seeking to de-risk and a robust capital...

Investing.com -- RBC Capital Markets analysts have highlighted five key developments shaping the gold equities sector, offering insight into the factors influencing investor...